Incyte: Phase III Ruxolitinib vs BAT with Corticosteroid -Refractory GvHD - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn about the safety and effectiveness of the drug ruxolitinib in patients with moderate to severe corticosteroid refractory chronic graft vs host disease.
Chronic graft vs host disease that is refractory (does not respond) to steroids
Who Can Participate in the Study?
Patients older than 12 who have been diagnosed with moderate or severe chronic graft vs host disease and had an allogeneic stem cell transplant.
What is Involved?
If you choose to join this study, you will
- Be randomized (as in the flip of a coin) to receive
-- A study drug called I11ruxolitinib by mouth twice a day or
-- Best available therapy (selected by your physician)
- You will be treated or followed for three years
- You must be able to swallow pills